Xilio Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Xilio Therapeutics R&D Spending Growth & History (XLO)
Xilio Therapeutics's r&d spending was $56.0M for fiscal 2025.
View full Xilio Therapeutics company overviewXilio Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $56.0M | $14.8M | +35.98% |
| 2024 | 2024-12-31 | $41.2M | −$10.9M | −20.95% |
| 2023 | 2023-12-31 | $52.1M | −$7.1M | −11.93% |
| 2022 | 2022-12-31 | $59.2M | $8.0M | +15.65% |
| 2021 | 2021-12-31 | $51.2M | $7.3M | +16.57% |
| 2020 | 2020-12-31 | $43.9M | — | — |
Xilio Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.6M | −$771,000 | −5.03% |
| Q1 2026 | 2026-03-31 | $19.8M | $11.6M | +139.92% |
| Q4 2025 | 2025-12-31 | $18.1M | $9.3M | +105.09% |
| Q3 2025 | 2025-09-30 | $14.3M | $3.6M | +33.11% |
| Q2 2025 | 2025-06-30 | $15.3M | $4.1M | +36.68% |
| Q1 2025 | 2025-03-31 | $8.3M | −$2.1M | −20.52% |
| Q4 2024 | 2024-12-31 | $8.8M | −$2.9M | −24.71% |
| Q3 2024 | 2024-09-30 | $10.8M | −$292,000 | −2.64% |
| Q2 2024 | 2024-06-30 | $11.2M | −$2.0M | −15.15% |
| Q1 2024 | 2024-03-31 | $10.4M | −$5.7M | −35.53% |
| Q4 2023 | 2023-12-31 | $11.7M | −$3.3M | −21.74% |
| Q3 2023 | 2023-09-30 | $11.1M | −$2.0M | −15.24% |
| Q2 2023 | 2023-06-30 | $13.2M | −$3.0M | −18.64% |
| Q1 2023 | 2023-03-31 | $16.1M | $1.2M | +8.12% |
| Q4 2022 | 2022-12-31 | $15.0M | $3.6M | +32.11% |
| Q3 2022 | 2022-09-30 | $13.0M | $2.6M | +24.53% |
| Q2 2022 | 2022-06-30 | $16.2M | −$1.5M | −8.45% |
| Q1 2022 | 2022-03-31 | $14.9M | $3.3M | +28.39% |
| Q4 2021 | 2021-12-31 | $11.4M | — | — |
| Q3 2021 | 2021-09-30 | $10.5M | −$990,000 | −8.64% |
| Q2 2021 | 2021-06-30 | $17.7M | — | — |
| Q1 2021 | 2021-03-31 | $11.6M | — | — |
| Q3 2020 | 2020-09-30 | $11.5M | — | — |
Xilio Therapeutics r&d spending trends
Over the last five fiscal years, Xilio Therapeutics's r&d spending increased from $43.9M to $56.0M, a change of $12.1M. The latest reported quarter, Q2 2026, shows $14.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics source filings ↗